Doctors who immediately viewed FDG-PET findings in cases of suspected Alzheimer's disease handled treatment differently than those who did not see the findings for two years, according to University of California, Los Angeles, researchers. Among patients whose doctors saw the scans right away, 40% were treated with dementia drugs within the initial six months of the two-year study while none of those whose doctors did not see the scans until two years later were treated within the first six months. Just 12% of patients in the delayed group received proper medication by the end of the first year. Researchers concluded that FDG-PET not only aids in early Alzheimer's disease diagnosis but also helps expedite treatment.

Related Summaries